Immediate Release

DIMERIX INVESTOR CALL & PRESENTATION

MELBOURNE, Australia, 1 March 2022: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company invites shareholders to attend its investor webinar held today at 11am (AEDT) 1 March 2022.

The webinar will cover Dimerix' activities, including the announcement regarding the changes to the REMAP-CAP COVID-19 study.

Interested parties can register for the webinar using this link:
https://zoom.us/webinar/register/WN_q1mnHbYTStCIbQ_CIejUwg

An investor presentation is attached to this announcement. Participants may submit questions during registration or during the session.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on [LinkedIn] and [Twitter]

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease[1]. DMX-200 is protected by granted patents in various territories until 2032, with additional applications submitted that may extend the protection to 2042 if granted.

DMX-200 has demonstrated encouraging data that could provide meaningful clinical outcomes for patients with kidney disease across 4 clinical studies to date[1]. DMX-200 is also under investigation as a potential treatment for patients with COVID-19 in two separate studies: REMAP-CAP and CLARITY 2.0.

References

[1] ASX releases: 12Jul17, 18Oct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21

Dimerix

(ASX:DXB)

Investor Briefing

01 March 2022

Authorised for lodgment by the Board of the Company

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

About Dimerix

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease

Advancing **three Phase 3** clinical studies

Demonstrated **clinical efficacy**[1]; drug well understood, with **strong safety profile**[1]

Patent protected products with **commercial manufacturing** established

Strong outlook with potential for **significant value**[2] upside

Dimerix

[1] *ASX releases: 12Jul17, 18Oct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21*
[2] *See slides 8 and 13 for market potential*

Corporate overview

Ticker Symbol	Cash Balance (31Dec21)	Market Capitalisation	Share price	Total ordinary shares on issue	Average volume	Top 20 Shareholders own
ASX:DXB	A$16.3 million	~A$58 million	~A$0.18	320,873,666	1,177,054	35%

Share price

Top shareholders

Position	Holder Name	Holding	% IC
1	Mr Peter Meurs	44,179,309	13.8%
2	Merchant Group & Nominees	17,925,000	5.6%
3	Mr Andrew & Mrs Melinda Coates	8,100,000	2.5%
4	Bavaria Bay Pty Ltd	7,316,992	2.3%
5	Yodambao Pty Ltd	6,362,603	2.0%
6	Solequest Pty Ltd & Nominees	3,387,302	1.1%
7	Pfleger Family A/C & Nominees	3,137,874	1.0%
8	Tamer Yigit Property Group Pty Ltd	3,101,343	1.0%
9	Rubi Holdings Pty Ltd	2,500,000	0.8%
10	Jampaso Pty Ltd and Nominees	2,377,355	0.7%
TOTAL (TOP 10)		**98,387,778**	**30.7%**

Dimerix

Development pipeline

Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Key milestones
DMX-200	Focal Segmental Glomerular Sclerosis (FSGS)					Phase 2a demonstrated encouraging efficacy & safety[1]; Phase 3 underway with regulatory &/or ethics authorisation in multiple countries[2], recruitment of 1st patients planned Q1 22, 1st interim data anticipated H1 23[3]
	Diabetic Kidney Disease					Phase 2 demonstrated promising efficacy and safety[1], planning of next study design underway
	Late COVID pneumonia – REMAP-CAP					Recruitment underway across Europe[4], initial data anticipated Q1 22[3]
	Early COVID respiratory – CLARITY 2.0					Recruitment underway across India[5], ethics approval in Australia[6], interim data from India anticipated Q1 22[3]
DMX-700	Chronic Obstructive Pulmonary Disease (COPD)					Pre-clinical studies underway to support entry into clinical studies; data anticipated Q2 22
DMX-xxx	Undisclosed (multiple)					Additional target opportunities identified using Receptor-HIT; preliminary exploratory work underway

Dimerix

[1] ASX releases: 12Jul17, 18Oct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21
[2] ASX releases: 21Oct21, 01Feb22 (Australia, Denmark); + Taiwan approved on 08Feb22
[3] Subject to recruitment
[4] ASX release: 23Apr21, 16Dec21
[5] ASX release: 11Jan22
[6] ASX release: 23Dec21

COVID-19 Respiratory Complications

Potential benefits of DMX-200

Antiviral medications:

Typically effective at preventing damage caused by a virus when administered

within 3-5 days of infection[1]

when many are asymptomatic

DMX-200:

Does not rely on early inhibition of viral replication

–

DMX-200 aims to prevent damaging immune response regardless of vaccination or antiviral treatment

DMX-200:

May be beneficial for patients with a wide range of respiratory diseases in addition to COVID[2]

Antivirals are usually very specific for a virus and sometimes even the particular strain of the virus[1]

Dimerix

1. *Brown L et al (2021) Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial: DOI: 10.1186/s13063-021-05139-2*
2. *Based on Szabo, et al., 2020; Merad, et al., 2020; Xiong, et al, 2020; Wu, et al., 2021; Chen, et al., 2009; Yong, et al., 2016*

Two Phase 3 studies in COVID-19 patients

REMAP-CAP

Patients were randomised patients to receive one of:

1. Angiotensin receptor blocker (ARB) alone
2. Angiotensin converting enzyme (ACE) inhibitor alone
3. **ARB simultaneously with DMX-200**
4. No RAS inhibitor (no placebo)

NHMRC Clinical Trials Centre

THE UNIVERSITY OF SYDNEY

REMAP-CAP: COVID-19 pneumonia in ICU

- >779 patients recruited to the study domain
- WHO endorsed study
- Primary endpoint = 21 day mortality

Funded by European Union through H2020 "Rapid European COVID-19 Emergency Research response" (RECOVER) project

CLARITY 2.0: COVID-19 respiratory complications

- Recruiting >600 patients in India and Australia
- Primary endpoint = 14 day WHO Clinical Health Score

Run through the NHMRC Clinical trials centre and the University of Sydney

Secondary endpoint: recovery and quality of life post hospitalisation (long-COVID assessment)

Initial study data anticipated Q1 2022

Dimerix

Kidney Disease Development Overview

FSGS phase 3 study design

ACTION3
FSGS CLINICAL STUDY

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB



- Stabilise ARB and any other medications (as appropriate)
- 1st dose
- 1st interim analysis; n=72, proteinuria at week 35
- 2nd analysis Accelerated Approval endpoint; n=144* (72 1st analysis + 72), proteinuria + eGFR at week 35
- Final analysis (n=286) eGFR slope at week 104

Dimerix

ARB: Angiotensin Receptor Blocker
**Subject to recruitment rate and conditional power*
Accelerated endpoint: Marketing approval for serious conditions that fill an unmet medical need based on a surrogate or an intermediate clinical endpoint

FSGS phase 3 study locations

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB

Global study with ~70 sites in 12 countries:

Country	Regulatory and/or ethics approval to proceed
Australia	✓
Argentina	✓
Brazil	
Denmark	✓
France	✓
Hong Kong	
New Zealand	✓
South Korea	
Spain	
Taiwan	✓
UK	
USA	

Corporate Outlook

Potential value driving events

2021

- ✓ DMX-200 demonstrated **encouraging clinical efficacy** and **strong safety profile** across multiple Phase 2 renal clinical studies
- ✓ Consistent advice received from **FDA, EMA and UK MHRA** on FSGS Phase 3 study design
- ✓ Orphan Drug Designation/**accelerated approval pathway** granted by US FDA, EU EMA and UK MHRA for FSGS
- ✓ Two independent Phase 3 clinical studies underway in patients with **COVID-19 respiratory complications**
- ✓ DMX-200 **manufacturing process optimised** to improve commercial scalability and global logistics
- ✓ DMX-700 in COPD progressed further towards **clinical development**
- ✓ Expansion of **IP portfolio**
- ✓ Strong **financial position**

2022

- ✓ FSGS **ethics approval** and clinical **site initiations**
- ❑ FSGS Phase 3 study **recruitment** and first patient **first dose**
- ❑ REMAP-CAP Phase 3 COVID-19 study recruitment and **top line data**
- ❑ CLARITY 2.0 Phase 3 COVID-19 study recruitment and **top line data**
- ❑ DMX-700 for Chronic Obstructive Pulmonary Disease progression towards **clinical study**
- ❑ Diabetic kidney disease **clinical study** design and next steps
- ✓ Further expansion of **IP portfolio**
- ❑ FSGS **Phase 3 study Part 1 analysis** and progression to Part 2

Dimerix

Dimerix

A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

Advancing three Phase 3 opportunities

Well positioned to deliver against strategic plan

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.